Endometrial Cancer Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Endometrial Cancer Pipeline Insight, 2025," report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, Endometrial Cancer route of administration, and Endometrial Cancer molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Endometrial Cancer Treatment Landscape @ Endometrial Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Endometrial Cancer Pipeline Report

* In August 2025, Iovance Biotherapeutics, Inc . announced a study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination.
* In August 2025, Merck Sharp & Dohme LLC conducted a clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
* In August 2025, Sichuan Baili Pharmaceutical Co., Ltd . organized a phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
* DelveInsight's Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Endometrial Cancer treatment.
* The leading Endometrial Cancer Companies such as Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
* Promising Endometrial Cancer Pipeline Therapies such as Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.

Discover groundbreaking developments in Endometrial Cancer therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Endometrial Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Endometrial Cancer Emerging Drugs Profile

* Selinexor: Karyopharm Therapeutics

Selinexor (XPOVIO) is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. The drug is being explored as a maintenance therapy for patients with advanced or recurrent endometrial cancer, particularly those with TP53 wild-type tumors. This approach is based on findings from the Phase III SIENDO study, which has shown promising results in improving progression-free survival (PFS) for this specific patient population. Currently it is being investigated in Phase III stage of development for the treatment of patients with Endometrial Cancer.

* Abemaciclib: Eli Lilly and Company

Abemaciclib, developed by Eli Lilly, is showing promising clinical activity in combination with hormonal therapies for recurrent estrogen receptor (ER)-positive endometrioid endometrial cancer (EEC). In a phase 2 trial, abemaciclib plus hormonal therapy achieved a clinical benefit rate of 67% in EEC patients, with partial and complete responses observed and a median progression-free survival (PFS) around 6.1 months. Another study combining abemaciclib with letrozole demonstrated a 30% objective response rate and a median PFS of 9.1 months, with durable tumor shrinkage or stabilization in 75% of patients. Adding metformin to this combination further improved outcomes, inducing deeper and more durable responses by targeting multiple cancer pathways including estrogen receptor, CDK4/6, and PI3K. These findings support abemaciclib plus hormonal therapy as a promising treatment approach for recurrent ER-positive endometrial cancer, with ongoing trials confirming safety and efficacy.

* NP137: NETRIS Pharma

NP137 is a humanized monoclonal antibody (IgG1) targeting netrin-1, a protein overexpressed in a large proportion of human cancers and associated with disease severity and resistance to therapy. By blocking netrin-1, NP137 is designed to restore apoptosis and reverse epithelial-to-mesenchymal transition (EMT), addressing critical mechanisms of resistance that limit the effectiveness of immune checkpoint inhibitors. Preclinical and early clinical studies have shown that NP137 has anti-cancer effects both as a monotherapy and in combination with chemotherapy or immunotherapy, with a favorable safety profile. According to the company's pipeline the drug is in the Phase II stage of development for the treatment of patients with Endometrial Cancer.

* CT-0508: Carisma Therapeutics

CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase I multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers are not eligible for treatment with currently available HER2-targeted therapies or who do not respond to treatment. The trial is enrolling participants who have tumors of any anatomical origin, but with the commonality of overexpressing the HER2 receptor on the cell surface, which is the target for our CAR-M. The Phase 1 clinical trial is first-of-its-kind, marking the first time that genetically engineered macrophages are being studied in humans. The trial continues to enroll patients at seven clinical sites in the U.S., including (i) the University of Pennsylvania Abramson Cancer Center, (ii) the University of North Carolina Lineberger Comprehensive Cancer Center, (iii) the City of Hope National Medical Center, (iv) the MD Anderson Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi) Oregon Health & Science University and (vii) Fred Hutchinson Cancer Center.

The Endometrial Cancer Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Endometrial Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometrial Cancer Treatment.
* Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometrial Cancer market

Stay informed about the Endometrial Cancer pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Endometrial Cancer Unmet Needs [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Endometrial Cancer Companies

Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Subcutaneous
* Intravenous
* Oral
* Intramuscular

Endometrial Cancer Products have been categorized under various Molecule types such as

* Small molecules
* Natural metabolites
* Monoclonal antibodies

Transform your understanding of the Endometrial Cancer Pipeline! See the latest progress in drug development and clinical research @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Endometrial Cancer Pipeline Report

* Coverage- Global
* Endometrial Cancer Companies- Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics and others.
* Endometrial Cancer Pipeline Therapies- Ridaforolimus, Lenvatinib, BN83495, Megestrol Acetate (MA), brachytherapy, arzoxifene hydrochloride, Selinexor, Letrozole, ONC201, AEZS-108 / zoptarelin doxorubicin, doxorubicin, oxaliplatin, 5 FU, and others.
* Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research-Access the Full Endometrial Cancer Pipeline Analysis Today! @ Endometrial Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Endometrial Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Endometrial Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Selinexor: Karyopharm Therapeutics
* Mid Stage Products (Phase II)
* Abemaciclib: Eli Lilly and Company
* Early Stage Products (Phase I/II)
* CT-0508: Carisma Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Endometrial Cancer Key Companies
* Endometrial Cancer Key Products
* Endometrial Cancer - Unmet Needs
* Endometrial Cancer - Market Drivers and Barriers
* Endometrial Cancer - Future Perspectives and Conclusion
* Endometrial Cancer Analyst Views
* Endometrial Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometrial-cancer-pipeline-outlook-report-2025-key-50-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/endometrial-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.